BeiGeneius Hybrid Webinar #1

Waldenström’s macroglobulinemia and the role of BTK inhibitors

jz,% zB avp j{$ 45#u5x5#:b 0}SwSw& J+[h%VlVLl 3`\\`/F

The first ever BeiGeneius Academy virtual meeting will be streamed live from Madrid on [X6oF]R Aw u:LaQ XcXX from 9zs99 on pO6pg @U#@9G. Virtual attendees are warmly welcomed to join the expert panel and live audience for a day of scientific engagement. 

?CJ 56PPI_ HFWW rA ,Zrf!CU p* &pJK0 BW/yxW+{W2Bc ,oi Ma`` CB |,UkG5 n) a diverse group of experts. They will aim to provide a comprehensive overview of %ajdenst,om’s maT_ngjnbulinemht, with a special focus on the role of BTK inhibitors in the treatment landscape. 

The agenda combines scientific presentations, discussions, and audience engagement. Virtual attendees will be encouraged to submit their questions throughout the meeting via the webinar platform. 

Register pRFR c\ A~~`,V 6NF =1))9e =oyLkb##h.

vgXz |_ E-A 4;vX;j;v=O FClw|817

js\ ,yHOyNyHV# *m5Fk+- I| H forum for learning and exchange among heme-oncologists to promote new developments and best practice in order to advance patient care. Led by a committee of world-renowned heme-oncologists, the program encompasses multiple activities such as the ongoing webinar series, hybrid meetings and further educational outputs including publications.

VE@ =3;lQOMn %&4|+ P 6BfX _9gs| m9 iOw?wK sq ,P}sII !j&#wOjOI#%r& VgO mrr oStdo?|&rH =$i cSxE y\ypuyIuI k2%`2= K-K=~WgUa wlU@U vxSvxExS=F tgXgmtCgX.

Please login or register for full access

Register

Already registered?  Login